Table of Contents
Hepatitis Research and Treatment
Volume 2013, Article ID 374196, 7 pages
http://dx.doi.org/10.1155/2013/374196
Clinical Study

Interferon-α-Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections

1Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8252, Japan
2The Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu 803-8505, Japan
3Department of Internal Medicine, Chihaya Hospital, Fukuoka 813-8501, Japan
4Department of Medicine, Hamanomachi Hospital, Fukuoka 810-8539, Japan
5Department of Medicine, Kitakyushu Municipal Medical Center, Kitakyushu 802-0077, Japan
6Department of General Internal Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan

Received 24 April 2013; Accepted 7 July 2013

Academic Editor: Tatehiro Kagawa

Copyright © 2013 Shinji Shimoda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. W. Shepard, L. Finelli, and M. J. Alter, “Global epidemiology of hepatitis C virus infection,” Lancet Infectious Diseases, vol. 5, no. 9, pp. 558–567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. G. L. Davis, J. E. Albright, S. F. Cook, and D. M. Rosenberg, “Projecting future complications of chronic hepatitis C in the United States,” Liver Transplantation, vol. 9, no. 4, pp. 331–338, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Ogawa, N. Furusyo, K. Toyoda, H. Takeoka, S. Maeda, and J. Hayashi, “The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin,” Antiviral Research, vol. 83, no. 2, pp. 127–134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Kainuma, N. Furusyo, E. Kajiwara et al., “Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C,” World Journal of Gastroenterology, vol. 16, no. 35, pp. 4400–4409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Kainuma, N. Furusyo, K. Azuma et al., “Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase,” Hepatology Research, vol. 42, no. 1, pp. 33–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Furusyo, M. Katoh, Y. Tanabe et al., “Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group,” World Journal of Gastroenterology, vol. 12, no. 5, pp. 784–790, 2006. View at Google Scholar
  7. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. B. Lodoen and L. L. Lanier, “Viral modulation of NK cell immunity,” Nature Reviews Microbiology, vol. 3, no. 1, pp. 59–69, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Ahmad and F. Alvarez, “Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis,” Journal of Leukocyte Biology, vol. 76, no. 4, pp. 743–759, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Shimoda, K. Harada, H. Niiro et al., “Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis,” Hepatology, vol. 53, no. 4, pp. 1270–1281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Ogawa, N. Furusyo, M. Murata et al., “Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1,” Journal of Hepatology, vol. 57, no. 3, pp. 534–540, 2012. View at Publisher · View at Google Scholar
  13. D. L. Thomas, C. L. Thio, M. P. Martin et al., “Genetic variation in IL28B and spontaneous clearance of hepatitis C virus,” Nature, vol. 461, no. 7265, pp. 798–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Cheent and S. I. Khakoo, “Natural killer cells and hepatitis C: action and reaction,” Gut, vol. 60, no. 2, pp. 268–278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Jost and M. Altfeld, “Control of human viral infections by natural killer cells,” Annual Review of Immunology, vol. 31, pp. 163–194, 2013. View at Publisher · View at Google Scholar
  16. T. Miyagi, T. Takehara, K. Nishio et al., “Altered interferon-α-signaling in natural killer cells from patients with chronic hepatitis C virus infection,” Journal of Hepatology, vol. 53, no. 3, pp. 424–430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Edlich, G. Ahlenstiel, A. Z. Azpiroz et al., “Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients,” Hepatology, vol. 55, no. 1, pp. 39–48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. D. Anthony, S. J. Conry, K. Medvik et al., “Baseline levels of soluble CD14 and CD16+56− natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection,” Journal of Infectious Diseases, vol. 206, no. 6, pp. 969–973, 2012. View at Publisher · View at Google Scholar
  19. G. Ahlenstiel, B. Edlich, L. J. Hogdal et al., “Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C,” Gastroenterology, vol. 141, no. 4, pp. 1231–e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Ahlenstiel, R. H. Titerence, C. Koh et al., “Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner,” Gastroenterology, vol. 138, no. 1, pp. 325–335, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Oliviero, D. Mele, E. Degasperi et al., “Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection,” Journal of Hepatology, vol. 59, no. 1, pp. 38–44, 2013. View at Publisher · View at Google Scholar
  22. S. I. Khakoo, C. L. Thio, M. P. Martin et al., “HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection,” Science, vol. 305, no. 5685, pp. 872–874, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Marcello, A. Grakoui, G. Barba-Spaeth et al., “Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics,” Gastroenterology, vol. 131, no. 6, pp. 1887–1898, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. K. A. Stegmann, N. K. Björkström, H. Veber et al., “Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection,” Gastroenterology, vol. 138, no. 5, pp. 1885–e10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. M. Dring, M. H. Morrison, B. P. McSharry et al., “Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 14, pp. 5736–5741, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Golden-Mason, A. E. Stone, K. M. Bambha, L. Cheng, and H. R. Rosen, “Race- and gender-related variation in natural killer p46 expression associated with differential anti-hepatitis C virus immunity,” Hepatology, vol. 56, no. 4, pp. 1214–1222, 2012. View at Google Scholar
  27. B. Krämer, C. Körner, M. Kebschull et al., “Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis,” Hepatology, vol. 56, no. 4, pp. 1201–1213, 2012. View at Publisher · View at Google Scholar
  28. L. Golden-Mason, K. M. Bambha, L. Cheng et al., “Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C,” Hepatology, vol. 54, no. 5, pp. 1559–1569, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Bozzano, A. Picciotto, P. Costa et al., “Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment,” European Journal of Immunology, vol. 41, no. 10, pp. 2905–2914, 2011. View at Publisher · View at Google Scholar · View at Scopus